Organon & Co. announced that the FDA has extended the review period for VTAMA cream by three months, now due on March 12, 2025, with no safety or efficacy concerns raised by the FDA.
AI Assistant
ORGANON & CO
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.